HUMAN PROTEIN DIFFERENTIAL DISPLAY ASSAY ICAT-ULC-MS/MS

人类蛋白质差异显示测定 ICAT-ULC-MS/MS

• 批准号: 6311048
• 负责人: Babak Esmaeli-Azad
• 金额: $ 14.31万
• 依托单位: BIOARRAY TECHNOLOGIES, INC.
• 依托单位国家: 美国
• 财政年份: 2001
• 资助国家: 美国
• 起止时间: 2001-08-01 至 2002-01-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6311048
• 关键词: differential display technique; immunoaffinity chromatography; mass spectrometry; neoplastic cell; phosphorylation; proteomics; technology /technique development; tissue /cell culture; tyrosine

DESCRIPTION: (Applicant's description) Development and testing of a protein differential display assay system, for proteomes of higher eukaryotes, using isotope-coded affinity tags (ICAT) and microcapillary liquid chromatography tandem mass spectrometry (uLC-MS/MS), is proposed. This system includes specific immunoaffinity capture of proteins during CAT analysis. Initial Phase I studies are proposed for development and optimization of phosphotyrosine specific protein differential display assay using a well characterized phosphotyrosine specific antibody and human carcinoma cells in culture. In Phase II, assays for other cell types and tissues will be developed. In addition, subtraction of high abundant and enrichment of low abundant proteins, in crude protein extracts, will be incorporated. Phase II studies also include use of novel CATs for comprehensive analysis of post-translational modifications.ln full development, this assay system provides for comprehensive analysis of the complex proteomes such as that of human. PROPOSED COMMERCIAL APPLICATION: Not available

描述：（申请人的描述）蛋白质的开发和测试 高等真核生物蛋白质组差异显示分析系统， 同位素编码亲和标签（ICAT）和微毛细管液相色谱 串联质谱（uLC-MS/MS）。该系统包括 在CAT分析期间特异性免疫亲和捕获蛋白质。初始阶段 I研究提出了开发和优化磷酸酪氨酸 使用良好表征的特异性蛋白质差异显示分析 磷酸酪氨酸特异性抗体和培养的人癌细胞。在 第二阶段，将开发用于其他细胞类型和组织的测定。在 高丰度蛋白质的添加、消减和低丰度蛋白质的富集， 在粗蛋白提取物中，将被掺入。II期研究还包括 使用新的CAT进行翻译后综合分析 在全面开发中，该测定系统提供了全面的 分析复杂的蛋白质组，如人类的蛋白质组。 拟议商业应用：不可用